Isotonitazene

Dopamine release (~200% over basal) was comparable to morphine at 100-fold higher dosessupported

NAc shell dopamine ~200% over basal. j.neuropharm.2022.109263

NAc shell dopamine elevation at CPP-inducing doses confirmed the reinforcement mechanismsupported

CPP confirmed. NAc dopamine significantly increased. j.taap.2025.117361

The median femoral whole blood concentration in three Swiss fatalities was 1.20 ng/mL, with the compound identified as the sole intoxicantsupported

Femoral blood median 1.20 ng/mL. Cause of death: acute isotonitazene intoxication in all three. j.forsciint.2021.110686

In broader forensic series, sub-ng/mL blood concentrations have been documented in fatal casessupported

Sub-ng/mL blood concentrations underscore high potencies. s00204-024-03774-7

The primary mechanism of death is severe respiratory depression via MOR agonism at brainstem respiratory centerssupported

Primary cause of death: prolonged respiratory depression. molecules30193890

Claim in safety — inconclusiveinconclusiveworking →

Slow MOR dissociation kinetics prolong the period of respiratory compromise and reduce sensitivity to naloxone reversal.supported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

The active metabolite N-desethyl isotonitazene is more potent than the parent compound at MOR, raising the possibility of delayed or worsening toxicity from metabolic conversion after initial exposure.supported

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR. s00204-024-03774-7

The active metabolite N-desethyl isotonitazene is more potent than the parent compound at MOR, raising the possibility of delayed or worsening toxicity from metabolic conversion after initial exposure.supported

N-desethyl isotonitazene among highest affinity. jpet.123.002052

Clinical case reports document incomplete reversal at standard dosessupported

Overdoses requiring high naloxone doses; incomplete naloxone response. j.therap.2024.05.004

High-dose naloxone, repeated administration, and/or continuous infusion should be anticipated in emergency managementsupported

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed. 15563650.2025.2504133

The mechanistic basis is slow receptor dissociation kinetics that impair competitive antagonism.supported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

United States (2020–2021): 144 isotonitazene-positive postmortem forensic blood samples — the most prevalent novel synthetic opioid in the study periodsupported

Isotonitazene (n=144) most prevalent. paf.0000000000000787

Switzerland (2021): 3 deaths; pure compound, sole intoxicantsupported

First three deaths in Europe. Purity >95-98%. Cause of death: acute isotonitazene intoxication in all three. j.forsciint.2021.110686

France (2023): 9 cases over 6 weeks (March–April 2023) including 1 death and 1 ICU admission; 6 men and 3 women, mean age 44.9 yearssupported

9 cases in south France Mar-Apr 2023; 1 death; incomplete naloxone response. j.therap.2024.05.004

France (lethal case): First documented fatality with complete postmortem parent and metabolite distributionsupported

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues. j.forsciint.2025.112763

Norway (2021–2024): 36 nitazene-related deaths; 94.4% male, median age 29; over 90% polydrug, 50% with designer benzodiazepinessupported

36 nitazene-related deaths Norway 2021-2024. 94.4% male, median age 29. >90% polydrug; 50% designer benzodiazepines. j.forsciint.2025.112794

Sweden (2020–2024): 57 nitazene autopsy casessupported

57 nitazene autopsy cases Sweden Dec 2020-Dec 2024. s00204-026-04407-x

Nitazene-related UK mortality may be systematically missed due to postmortem instability of the compounds — degradation before toxicological analysis produces false-negative results.supported

UK investigation of potential underestimation of nitazene mortality due to postmortem stability issues. 15563650.2025.2601141

The vast majority of nitazene fatalities involve polydrug combinations, most commonly with other opioids, benzodiazepines (including designer benzodiazepines such as flualprazolam), and/or alcoholsupported

>90% polydrug; 50% designer benzodiazepines. j.forsciint.2025.112794

The vast majority of nitazene fatalities involve polydrug combinations, most commonly with other opioids, benzodiazepines (including designer benzodiazepines such as flualprazolam), and/or alcoholsupported

Systematic review of benzimidazole opioid intoxications and fatalities. Reviews toxicological data from all BO-related cases. ftd.0000000000000970

Norwegian data show that over 90% of nitazene-related deaths involved multiple substances, with designer benzodiazepines present in 50% of casessupported

>90% polydrug; 50% designer benzodiazepines. j.forsciint.2025.112794

Claim in safety — inconclusiveinconclusiveworking →

Standard immunoassay urine drug screens — including fentanyl test strips — do not detect isotonitazene or other nitazenessupported

Traditional toxicology may miss at low postmortem concentrations. s40122-023-00481-6

The sub-ng/mL concentrations in biological samples require highly sensitive LC-MS/MS or high-resolution mass spectrometry (HRMS) methods for reliable quantificationsupported

Analytical challenges at sub-ng/mL concentrations. molecules30193890

The sub-ng/mL concentrations in biological samples require highly sensitive LC-MS/MS or high-resolution mass spectrometry (HRMS) methods for reliable quantificationsupported

Traditional toxicology may miss at low postmortem concentrations. s40122-023-00481-6

The sub-ng/mL concentrations in biological samples require highly sensitive LC-MS/MS or high-resolution mass spectrometry (HRMS) methods for reliable quantificationsupported

Analytical methods at sub-ng/mL. Reviews all progress in forensic toxicology of nitazene class. s00204-025-04102-3

Product mislabeling compounds the detection problem: the original identification paper found isotonitazene sold as "etonitazene", and a drug-checking service later found a sample labeled as isotonitazene that actually contained N-desethyl etonitazene — a different, highly potent compound.supported

Sold as etonitazene on online markets. dta.2738

Product mislabeling compounds the detection problem: the original identification paper found isotonitazene sold as "etonitazene", and a drug-checking service later found a sample labeled as isotonitazene that actually contained N-desethyl etonitazene — a different, highly potent compound.supported

Sample sold as isotonitazene contained N-desethyl etonitazene at high purity. j.jpba.2024.116453

Clinical case reports describe only profound CNS depression (unconsciousness, coma) and respiratory failure — patients are not communicative or conscious during the documented presentations.supported

Cause of death: acute isotonitazene intoxication in all three. j.forsciint.2021.110686

Clinical case reports describe only profound CNS depression (unconsciousness, coma) and respiratory failure — patients are not communicative or conscious during the documented presentations.supported

Overdoses requiring high naloxone doses; 1 death; incomplete naloxone response. j.therap.2024.05.004

Conditioned place preference (CPP) was established in mice at 0.01–0.05 mg/kgsupported

CPP confirmed. j.taap.2025.117361

The investigators concluded that isotonitazene carries a "high risk of forming drug dependence and reward effects via the dopaminergic nervous system".supported

CPP confirmed. NAc dopamine significantly increased. D1/D2 antagonists also blocked locomotor effects. j.taap.2025.117361

Norwegian forensic data demonstrate that over 90% of nitazene-related deaths involved polydrug combinations, with designer benzodiazepines (especially flualprazolam) detected in 50% of casessupported

>90% polydrug; 50% designer benzodiazepines. j.forsciint.2025.112794

Polydrug opioid detection is documented in postmortem forensic case series.supported

Systematic review of benzimidazole opioid intoxications and fatalities. Reviews toxicological data from all BO-related cases. ftd.0000000000000970

Polydrug opioid detection is documented in postmortem forensic case series.supported

Mixed with fentanyl in many cases. paf.0000000000000787

Claim in safety — inconclusiveinconclusiveworking →

Isotonitazene's slow MOR dissociation kinetics reduce the effectiveness of standard naloxone dosingsupported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

Clinical case reports document incomplete reversal at standard doses, with high-dose or repeated naloxone administration required.supported

Overdoses requiring high naloxone doses; incomplete naloxone response. j.therap.2024.05.004

Clinical case reports document incomplete reversal at standard doses, with high-dose or repeated naloxone administration required.supported

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed. 15563650.2025.2504133

Claim in safety — inconclusiveinconclusiveworking →

Concurrent benzodiazepine use (absolute): Synergistic respiratory depression is the primary driver of polydrug nitazene fatalities. Combined use produces multiplicative respiratory depression risk.supported

>90% polydrug; 50% designer benzodiazepines. j.forsciint.2025.112794

Concurrent opioid use (absolute): Additive MOR-mediated respiratory depression.supported

Systematic review of benzimidazole opioid intoxications and fatalities. Reviews toxicological data from all BO-related cases. ftd.0000000000000970

Claim in safety — inconclusiveinconclusiveworking →

In rat analgesic assays, it is approximately 3.7 times more potent than fentanyl and roughly 1,500 times more potent than morphinesupported

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35. j.neuropharm.2022.109263

First identified on European online drug markets in 2019 and characterized the following year, isotonitazene was the inaugural nitazene-class compound to reach the illicit supplysupported

First identification and full chemical characterization of isotonitazene. Sold as etonitazene on online markets. dta.2738

It became the most prevalent novel synthetic opioid in United States forensic casework during 2020–2021, with 144 postmortem detections out of 384 total novel synthetic opioid casessupported

Jan 2020-Dec 2021: 384 blood samples positive for 8 NSOs. Isotonitazene (n=144) most prevalent. paf.0000000000000787

No clinical trials have been conducted, and the compound has no medical development history — the nitazene class was abandoned in the 1960s due to an unfavorable therapeutic indexsupported

Originally developed 1950s, abandoned due to high toxicity and unfavorable therapeutic index. 15563650.2025.2504133

Claim in summary — inconclusiveinconclusiveworking →

By the end of 2024, isotonitazene had catalyzed the emergence of 22 distinct nitazene analogues across Europe.supported

22 nitazene analogues identified in Europe by end 2024. Isotonitazene as the class catalyst since 2019. j.neuropharm.2025.110470

Isotonitazene binds MOR with Ki = 0.05–0.06 nM and activates it with EC₅₀ values ranging from 0.02 nM to 11.1 nM depending on assay system and endpointsupported

Ki 0.06 nM (rat cortex), 0.05 nM (CHO-MOR). EC50 0.99 nM (rat membrane), 0.71 nM (CHO-MOR). j.neuropharm.2022.109263

Isotonitazene binds MOR with Ki = 0.05–0.06 nM and activates it with EC₅₀ values ranging from 0.02 nM to 11.1 nM depending on assay system and endpointsupported

MOR EC50 11.1 nM, Emax 180% of hydromorphone. dta.2738

Isotonitazene binds MOR with Ki = 0.05–0.06 nM and activates it with EC₅₀ values ranging from 0.02 nM to 11.1 nM depending on assay system and endpointsupported

EC50 at MOR 0.02 nM vs morphine 34 nM, fentanyl 4.0 nM. j.taap.2025.117361

Efficacy (Emax) is comparable to the reference full agonist DAMGO and reaches 180% of hydromorphone in BRET-based reporter assayssupported

MOR EC50 11.1 nM, Emax 180% of hydromorphone. dta.2738

Efficacy (Emax) is comparable to the reference full agonist DAMGO and reaches 180% of hydromorphone in BRET-based reporter assayssupported

Higher potency than DAMGO; Emax comparable. j.neuropharm.2022.109263

Slow MOR dissociation kinetics — shared across the nitazene class — reduce sensitivity to naloxone reversalsupported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

The major metabolite, N-desethyl isotonitazene, exhibits higher MOR potency than the parent compound.supported

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR. s00204-024-03774-7

The major metabolite, N-desethyl isotonitazene, exhibits higher MOR potency than the parent compound.supported

N-desethyl isotonitazene among highest affinity. 13 with subnanomolar MOR affinity. jpet.123.002052

Clinical case reports document only profound respiratory depression and unconsciousnesssupported

Cause of death: acute isotonitazene intoxication in all three. j.forsciint.2021.110686

Clinical case reports document only profound respiratory depression and unconsciousnesssupported

Overdoses requiring high naloxone doses; 1 death; incomplete naloxone response. j.therap.2024.05.004

Reward and reinforcement are confirmed in animal models through conditioned place preference and nucleus accumbens dopamine elevation.supported

CPP confirmed. NAc dopamine significantly increased. j.taap.2025.117361

Isotonitazene is lethal at femoral blood concentrations as low as 1.20 ng/mL; some fatal cases show sub-ng/mL levelspartially supported

Femoral blood median 1.20 ng/mL. j.forsciint.2021.110686

Isotonitazene is lethal at femoral blood concentrations as low as 1.20 ng/mL; some fatal cases show sub-ng/mL levelssupported

Sub-ng/mL blood concentrations underscore high potencies. s00204-024-03774-7

Standard naloxone dosing may be insufficient for overdose reversal due to slow receptor dissociation kineticssupported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

Standard naloxone dosing may be insufficient for overdose reversal due to slow receptor dissociation kineticssupported

Overdoses requiring high naloxone doses; incomplete naloxone response. j.therap.2024.05.004

Animal data indicate high dependence liability through mesolimbic dopamine pathway activationsupported

CPP confirmed. NAc dopamine significantly increased. D1/D2 antagonists also blocked locomotor effects. j.taap.2025.117361

The vast majority of documented fatalities involve polydrug combinations, particularly with benzodiazepinessupported

>90% polydrug; 50% designer benzodiazepines. j.forsciint.2025.112794

Binding affinity is exceptionally high: Ki = 0.06 nM at rat cerebral cortex membranes and 0.05 nM at human MOR expressed in CHO cellssupported

Ki 0.06 nM (rat cortex), 0.05 nM (CHO-MOR). j.neuropharm.2022.109263

Functional potency, measured as EC₅₀ for MOR activation, varies with assay system — 11.1 nM in a BRET-based live cell reporter in HEK293 cells, 0.71 nM in CHO cells overexpressing human MOR, 0.99 nM in rat cerebral cortex membranes, and 0.02 nM in a separate in vitro cell assaysupported

MOR EC50 11.1 nM, Emax 180% of hydromorphone. dta.2738

Functional potency, measured as EC₅₀ for MOR activation, varies with assay system — 11.1 nM in a BRET-based live cell reporter in HEK293 cells, 0.71 nM in CHO cells overexpressing human MOR, 0.99 nM in rat cerebral cortex membranes, and 0.02 nM in a separate in vitro cell assaysupported

ITZ EC50 0.99 nM (rat membrane), 0.71 nM (CHO-MOR). j.neuropharm.2022.109263

Functional potency, measured as EC₅₀ for MOR activation, varies with assay system — 11.1 nM in a BRET-based live cell reporter in HEK293 cells, 0.71 nM in CHO cells overexpressing human MOR, 0.99 nM in rat cerebral cortex membranes, and 0.02 nM in a separate in vitro cell assaysupported

EC50 at MOR 0.02 nM vs morphine 34 nM, fentanyl 4.0 nM. j.taap.2025.117361

Maximal efficacy (Emax) reaches 180% of hydromorphone in BRET reporter assays and is comparable to DAMGO — the standard full MOR agonist reference — with no significant difference in Emax in CHO and cortex membrane preparationssupported

MOR EC50 11.1 nM, Emax 180% of hydromorphone. dta.2738

Maximal efficacy (Emax) reaches 180% of hydromorphone in BRET reporter assays and is comparable to DAMGO — the standard full MOR agonist reference — with no significant difference in Emax in CHO and cortex membrane preparationssupported

Higher potency than DAMGO; Emax comparable. j.neuropharm.2022.109263

Systematic screening of 19 nitazenes at human MOR, kappa-opioid receptor (KOR), and delta-opioid receptor (DOR) expressed in CHO cells showed KOR affinity 46- to 2,580-fold lower and DOR affinity 180- to 1,280-fold lower than MOR affinity.supported

19 nitazenes at MOR, KOR, DOR in CHO cells. KOR 46-2580x lower than MOR; DOR 180-1280x lower. jpet.123.002052

This slow off-rate correlates with reduced sensitivity to the competitive antagonist naloxone, providing a mechanistic explanation for the clinically observed incomplete reversal of nitazene overdoses with standard naloxone doses.supported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

This slow off-rate correlates with reduced sensitivity to the competitive antagonist naloxone, providing a mechanistic explanation for the clinically observed incomplete reversal of nitazene overdoses with standard naloxone doses.supported

Overdoses requiring high naloxone doses; incomplete naloxone response. j.therap.2024.05.004

This slow off-rate correlates with reduced sensitivity to the competitive antagonist naloxone, providing a mechanistic explanation for the clinically observed incomplete reversal of nitazene overdoses with standard naloxone doses.supported

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed. 15563650.2025.2504133

Induced fit docking (IFD) and metadynamic (MTD) simulations of isotonitazene at the MOR produced binding modes and conformational changes consistent with the in vitro and in vivo biological data.supported

In silico docking confirms binding. j.neuropharm.2022.109263

Under identical conditions, fentanyl ED₅₀ was 0.00578 mg/kg (approximately 3.7 times less potent) and morphine ED₅₀ was 2.35 mg/kg (approximately 1,500 times less potent).supported

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35. j.neuropharm.2022.109263

Taoussi and colleagues identified 12 metabolites of isotonitazene, with the primary metabolic routes being N-deethylation and O-dealkylation (isopropyl ether cleavage)supported

12 metabolites identified for isotonitazene. Main pathways: N-deethylation, O-dealkylation, O-glucuronidation. s00204-024-03735-0

The major circulating metabolite is N-desethyl isotonitazene, which exhibits higher MOR potency than the parent compound — an unusual and safety-critical findingsupported

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR. s00204-024-03774-7

The major circulating metabolite is N-desethyl isotonitazene, which exhibits higher MOR potency than the parent compound — an unusual and safety-critical findingsupported

N-desethyl isotonitazene among highest affinity. jpet.123.002052

Three metabolites (including N-desethyl isotonitazene) were detected in the first documented French fatality with full postmortem distribution analysis.supported

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues. j.forsciint.2025.112763

Claim in pharmacology — inconclusiveinconclusiveworking →

Hepatic concentrations were unexpectedly low compared to other opioids — an observation with implications for forensic toxicological interpretationsupported

Tissue distribution: brain, lungs, heart (highest); liver (lowest). j.forsciint.2021.110686

Claim in pharmacology — inconclusiveinconclusiveworking →

In rat microdialysis, isotonitazene 0.01 mg/kg iv produced approximately 200% increase in NAc shell dopamine over basal levels — a magnitude comparable to or exceeding morphine at 100-fold higher doses (1 mg/kg iv).supported

NAc shell dopamine ~200% over basal. j.neuropharm.2022.109263

In mice, dose-dependent locomotor stimulation at doses up to 0.05 mg/kg was blocked by naloxone (3 mg/kg), the selective MOR antagonist β-FNA (1 mg/kg), the D1 antagonist SCH23390 (0.5 mg/kg), and the D2 antagonist raclopride (6 mg/kg)supported

Dose-dependent locomotor stimulation. Naloxone and beta-FNA blocked effects. D1/D2 antagonists also blocked locomotor effects. j.taap.2025.117361

Conditioned place preference (CPP) was established at 0.01–0.05 mg/kg in mice, with concurrent NAc dopamine elevation at CPP-inducing dosessupported

CPP confirmed. NAc dopamine significantly increased. j.taap.2025.117361

As a potent MOR full agonist, isotonitazene is presumed to produce analgesia through this pathway — consistent with its in vivo analgesic ED₅₀ of 0.00156 mg/kg iv in rats.supported

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35. j.neuropharm.2022.109263

The primary lethal mechanism is respiratory depression via MOR agonism at brainstem respiratory centers, particularly the pre-Bötzinger complex and the parabrachial nucleussupported

Primary cause of death: prolonged respiratory depression. molecules30193890

Claim in neuroscience — inconclusiveinconclusiveworking →

Active metabolite contribution to toxicity: N-desethyl isotonitazene is more potent than the parent compound at MOR. What fraction of in vivo toxicity is attributable to the metabolite vs. the parent? Does metabolite accumulation explain cases of delayed respiratory depression?supported

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR. s00204-024-03774-7

Active metabolite contribution to toxicity: N-desethyl isotonitazene is more potent than the parent compound at MOR. What fraction of in vivo toxicity is attributable to the metabolite vs. the parent? Does metabolite accumulation explain cases of delayed respiratory depression?supported

N-desethyl isotonitazene among highest affinity. jpet.123.002052

The slow MOR dissociation kinetics of isotonitazene prolong the period of respiratory compromise, as the compound cannot be efficiently displaced from these receptors by standard naloxone doses.supported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

No longitudinal human data confirm this prediction, but the animal CPP and dopamine data are consistent with strong initial reinforcement that would drive rapid escalation.supported

CPP confirmed. NAc dopamine significantly increased. j.taap.2025.117361

Postmortem stability is a documented concern: nitazenes may degrade in biological specimens prior to toxicological analysis, potentially leading to underestimation of their involvement in fatalities.supported

UK investigation of potential underestimation of nitazene mortality due to postmortem stability issues. 15563650.2025.2601141

Isotonitazene is a positional isomer (regioisomer) of etonitazene, differing only in the alkoxy substituent on the pendant benzyl ring: isotonitazene carries a 4-isopropyloxy group where etonitazene has a 4-ethoxy group.supported

First identification and full chemical characterization of isotonitazene. dta.2738

Claim in chemistry — inconclusiveinconclusiveworking →

Three structural elements define isotonitazene's pharmacological profile:supported

First identification and full chemical characterization of isotonitazene. dta.2738

A 4-isopropyloxybenzyl group at C-2 of the benzimidazole. The isopropoxy chain distinguishes isotonitazene from etonitazene (ethoxy) and metonitazene (methoxy). Alkoxy chain length at this position is a principal determinant of potency within the nitazene class.supported

Alkoxy chain length influences nitazene potency at MOR both in vitro and in animal models. Isopropoxy group in isotonitazene relevant to its potency profile. s00213-023-06451-2

An N,N-diethylaminoethyl group at N-1 of the benzimidazole. N-deethylation of this group yields the metabolite N-desethyl isotonitazene, which — unusually — exceeds the parent compound in MOR potency.supported

N-desethyl isotonitazene among highest affinity. 13 with subnanomolar MOR affinity. jpet.123.002052

Claim in chemistry — not_supportednot supportedworking →

N-desethyl isotonitazene is a notable exception: it consistently shows higher MOR potency than the parent compound in both binding and functional assayssupported

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR. s00204-024-03774-7

In rat in vivo microdialysis, isotonitazene 0.01 mg/kg iv produced an approximately 200% increase in dialysate dopamine in the nucleus accumbens (NAc) shell over basal values — comparable to or exceeding morphine at 1 mg/kg iv, and greater than fentanyl at 0.01 mg/kg ivsupported

NAc shell dopamine ~200% over basal. j.neuropharm.2022.109263

Clinical case reports confirm that higher-than-standard naloxone doses, repeated administration, and/or continuous infusion have been required for overdose managementsupported

Overdoses requiring high naloxone doses; incomplete naloxone response. j.therap.2024.05.004

Clinical case reports confirm that higher-than-standard naloxone doses, repeated administration, and/or continuous infusion have been required for overdose managementsupported

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed. 15563650.2025.2504133

The most direct potency comparison comes from rat tail flick assays using intravenous administration under identical conditions:supported

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35. j.neuropharm.2022.109263

The isopropoxy substituent of isotonitazene places it in a distinct SAR tier from the ethoxy chain of etonitazene; the relationship between alkoxy chain length and potency has been systematically characterized.supported

Alkoxy chain length influences nitazene potency at MOR both in vitro and in animal models. Isopropoxy group in isotonitazene relevant to its potency profile. s00213-023-06451-2

While fentanyl overdoses are generally responsive to standard naloxone dosing protocols, nitazenes — including isotonitazene — display slow MOR dissociation kinetics that reduce the effectiveness of competitive antagonismpartially supported

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal. bph.17376

N-desethyl isotonitazene is more potent at MOR than the parent compound — a relationship not observed with the primary metabolites of fentanyl (norfentanyl, which is inactive) or morphine (morphine-6-glucuronide, which is active but formed through a different metabolic pathway)supported

N-desethyl isotonitazene among highest affinity. jpet.123.002052

Following its emergency scheduling in the US (August 2020), market surveillance showed a rapid shift to alternative nitazene analogues — particularly metonitazenesupported

Comprehensive review of SAR, market trends, detection strategies, legal framework. Isotonitazene as the class catalyst since 2019. j.neuropharm.2025.110470

Despite extraordinary potency at the mu-opioid receptor, the class was never advanced to clinical development: the therapeutic index — the ratio between effective and lethal doses — was too narrow for safe medical usesupported

Originally developed 1950s, abandoned due to high toxicity and unfavorable therapeutic index. 15563650.2025.2504133

Claim in history — inconclusiveinconclusiveworking →

The first documented European fatalities occurred in Switzerland in 2021 — three deaths in which isotonitazene was the sole identified intoxicant, present at high puritysupported

First three deaths in Europe. Purity >95-98% (NMR, GC-MS). Cause of death: acute isotonitazene intoxication in all three. j.forsciint.2021.110686

France identified its first domestic cases in March 2023, with a cluster of 9 cases (1 fatal, 1 ICU admission) occurring over six weeks in the southern part of the countrysupported

9 cases in south France Mar-Apr 2023; First French identification March 2023. 1 death. j.therap.2024.05.004

Isotonitazene was the first member of the 2-benzylbenzimidazole class to surface on online drug markets, initially identified in 2019supported

First identification and full chemical characterization of isotonitazene. Sold as etonitazene on online markets. dta.2738

The product was sold as undiluted powder at remarkably high purity: analysis showed greater than 95% purity by GC-MS and greater than 98% by proton NMR.supported

Purity >95-98% (NMR, GC-MS). Single highly pure compound confirmed by NMR and FT-IR. Compound sold undiluted — imminent danger. dta.2738

Isotonitazene was the most prevalent novel synthetic opioid detected in US forensic casework between January 2020 and December 2021, accounting for 144 of 384 total novel synthetic opioid detections in postmortem investigationssupported

Jan 2020-Dec 2021: 384 blood samples positive for 8 NSOs. Isotonitazene (n=144) most prevalent. paf.0000000000000787

Swedish autopsy data from 2020–2024 included 57 nitazene cases across multiple analogues.supported

57 nitazene autopsy cases Sweden Dec 2020-Dec 2024. s00204-026-04407-x

Blood: Median femoral whole blood concentration of 1.20 ng/mL in three Swiss fatalities. Sub-ng/mL concentrations have been documented in some fatal cases in broader forensic series.supported

Femoral blood median 1.20 ng/mL. j.forsciint.2021.110686

Blood: Median femoral whole blood concentration of 1.20 ng/mL in three Swiss fatalities. Sub-ng/mL concentrations have been documented in some fatal cases in broader forensic series.supported

Sub-ng/mL blood concentrations underscore high potencies. s00204-024-03774-7

Metabolite distribution: Three metabolites (including N-desethyl isotonitazene) were quantified in the first French lethal case with full postmortem analysis.supported

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues. j.forsciint.2025.112763

N-desethyl isotonitazene is pharmacologically active with higher MOR potency than the parent compoundsupported

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR. s00204-024-03774-7

In vitro and postmortem metabolic profiling has identified 12 metabolites of isotonitazenesupported

12 metabolites identified for isotonitazene in 10-donor pooled human hepatocytes. s00204-024-03735-0

Tissue distribution: Highest concentrations in brain, lung, and heart. Hepatic concentrations were unexpectedly low relative to other opioids — an observation that may lead to underestimation of isotonitazene involvement when liver tissue is used for screening.supported

Tissue distribution: brain, lungs, heart (highest); liver (lowest). j.forsciint.2021.110686

Standard immunoassay urine drug screens do not reliably detect isotonitazene or its metabolitessupported

Traditional toxicology may miss at low postmortem concentrations. s40122-023-00481-6

The low concentrations present in biological specimens (often sub-ng/mL) require highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) for reliable quantificationsupported

Traditional toxicology may miss at low postmortem concentrations. s40122-023-00481-6

Three Swiss fatalities (2021) — sole intoxicant, pure compoundsupported

First three deaths in Europe. Purity >95-98% (NMR, GC-MS). Cause of death: acute isotonitazene intoxication in all three. j.forsciint.2021.110686

One French fatality with complete postmortem distribution analysis of parent compound and metabolitessupported

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues. j.forsciint.2025.112763

The broader nitazene class was abandoned before clinical trials in the 1960s due to an unfavorable therapeutic index, and no nitazene analogue has been revisited for therapeutic development.supported

Originally developed 1950s, abandoned due to high toxicity and unfavorable therapeutic index. 15563650.2025.2504133

Nine cases in southern France (March–April 2023), including one death and one ICU admissionsupported

9 cases in south France Mar-Apr 2023; 1 death. j.therap.2024.05.004

36 nitazene-related deaths in Norway (2021–2024), with isotonitazene detected in earlier casessupported

36 nitazene-related deaths Norway 2021-2024. Escalation since June 2023. j.forsciint.2025.112794

The mechanistic implication is that once isotonitazene occupies MOR, naloxone at standard clinical doses cannot efficiently displace it — a finding consistent with the clinical observation of incomplete overdose reversalsupported

Overdoses requiring high naloxone doses; incomplete naloxone response. j.therap.2024.05.004

The mechanistic implication is that once isotonitazene occupies MOR, naloxone at standard clinical doses cannot efficiently displace it — a finding consistent with the clinical observation of incomplete overdose reversalsupported

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed. 15563650.2025.2504133

Emax reached 180% of hydromorphone in the BRET reporter system and showed no significant difference from the full agonist reference DAMGO in CHO and cortex membrane preparations.supported

MOR EC50 11.1 nM, Emax 180% of hydromorphone. dta.2738

Systematic profiling of 19 nitazene analogues at human MOR, KOR, and DOR expressed in CHO cells demonstrated that isotonitazene is highly MOR-selectivesupported

19 nitazenes at MOR, KOR, DOR in CHO cells. KOR 46-2580x lower than MOR; DOR 180-1280x lower. jpet.123.002052

N-desethyl isotonitazene — the primary Phase I metabolite formed by hepatic N-deethylation — shows higher MOR binding affinity and functional potency than the parent compound in competitive binding and functional assayssupported

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR. s00204-024-03774-7

Relative to fentanyl — the most widely known potent synthetic opioid — isotonitazene occupies a position of approximately 3.7-fold greater analgesic potency in rat models, with critically impaired naloxone reversibility and an active metabolite that fentanyl lackssupported

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35. j.neuropharm.2022.109263